Biogen (BIIB) EBT Margin (2009 - 2026)

Biogen (BIIB) has reported EBT Margin for 18 consecutive years, with 15.24% the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT Margin rose 244.0% year-over-year to 15.24%; the TTM figure through Mar 2026 stood at 16.33% (down 152.0% YoY), while the FY2025 annual figure was 15.74%, down 396.0% from the prior year.
• EBT Margin came in at 15.24% for Q1 2026 at Biogen, up from 2.46% in the prior quarter.
• The five-year high for EBT Margin was 54.66% in Q3 2022, with the low at 5.58% in Q3 2023.
• Average EBT Margin over 5 years is 20.52%, with a median of 18.29% recorded in 2024.
• Across the five-year window, EBT Margin jumped 4418 bps in 2022 and tumbled 6024 bps in 2023, its largest moves.
• Year by year, EBT Margin stood at 23.73% in 2022, then sank by 49 bps to 12.22% in 2023, then retreated by 3 bps to 11.88% in 2024, then tumbled by 121 bps to 2.46% in 2025, then soared by 720 bps to 15.24% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 15.24%, 2.46%, and 21.99% for Q1 2026, Q4 2025, and Q3 2025 respectively.